Abstract
Abstract Background The impact of Positive Airway Pressure (PAP) therapy on the use of oral antihypertensive drugs (OAHDs) in patients with obstructive sleep apnoea (OSA) remains unclear. This study aimed to evaluate the association between PAP use and the delivery of OAHDs. Methods Data from the Pays de la Loire Sleep Cohort were linked with the French health insurance database to quantify OAHD delivery in patients with hypertension at the initiation of PAP therapy. The primary endpoint was the change in OAHD score, reflecting the number of OAHD classes delivered. PAP use groups were defined as: termination, <4 hours/day, 4 to <6 hours/day, and ≥6 hours/day. Results The study included 2205 OSA patients (median [Q1-Q3] apnoea-hypopnea-index [AHI] of 39 [30–55] events/h), of whom 68% were male. The median age was 61 [54–68] years, BMI was 32.42 [28.95–36.43] kg/m 2 , and Epworth score was 10 [6–13]. After one year of PAP, the mean (SD) OAHD score decreased from 2.16 (1.11) to 2.13 (1.18) with no significant difference between PAP use groups. Respectively, 11.93% and 11.07% of patients experienced a decrease or increase in OAHD score, with no significant difference between PAP use groups. Multivariate analysis revealed that an increase in OAHD score was significantly positively associated with age, calcium channel blocker and number of consultations. A decrease in OAHD score was significantly associated with baseline OAHD score, number of consultations, loop diuretics and decrease in Medication Possession Ratio. Conclusion PAP use is not associated with a change in OAHD score after one year. SOURCE OF SUPPORT: This study was supported by the Institut de Recherche en Santé Respiratoire (IRSR) des Pays de Loire.